Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sital, Shah"'
Autor:
María Fernanda, Guerra-Veloz, Khin, Han, Kathryn, Oakes, David, Robertson, Almuthana, Mohamed, Mary, Cannon, Ashley, Barnabas, Sital, Shah, Rachel, Halford, Geoffrey, Dusheiko, Kosh, Agarwal
Publikováno v:
American Journal of Gastroenterology. 118:991-1000
Given the hepatitis C virus (HCV) burden and despite curative treatments, more efforts focused on scaling-up testing and treatment in homeless populations are needed. This project aimed to implement education and flexible on-site HCV testing, treatme
Autor:
Kathryn McDaniel, Alyssa E. Utz, Mikhail Akbashev, Katherine G. Fuller, Alison Boyle, Katherine Davidson, Fiona Marra, Sital Shah, Emily J. Cartwright, Aakriti A. Arora, Sarah DuPont, Lesley S. Miller
Publikováno v:
Journal of Viral Hepatitis. 29:1073-1078
Treatment for hepatitis C virus (HCV) with direct-acting antivirals (DAA) is advantageous over previous treatment options due to high efficacy, short treatment duration, and relatively few drug interactions. Similarly, direct oral anticoagulants (DOA
Publikováno v:
Journal of Hepatology. 75:324-332
Background & Aims Patients with autoimmune hepatitis (AIH) usually receive maintenance therapy with thiopurines, such as azathioprine (AZA) or mercaptopurine. Genetic polymorphisms in AZA metabolism can lead to variations in thioguanine nucleotide (T
Autor:
Andrew Radley, Sital Shah
Publikováno v:
The International journal of pharmacy practice.
Objective The World Health Organisation aims to eliminate Hepatitis C (HCV) by 2030. To achieve this, targeted testing needs to be widely available. Studies have demonstrated that community pharmacies can deliver effective targeted testing for HCV an
Autor:
Maria Guerra Veloz, Khin Aye Wint Han, Almuthana Mohamed, Kathryn Oakes, David Robertson, Mary D. Cannon, Ashley Barnabas, Sital Shah, Geoffrey Dusheiko, Kosh Agarwal
Publikováno v:
Journal of Hepatology. 77:S594
Publikováno v:
Hepatology (Baltimore, Md.)References. 73(6)
Publikováno v:
Abstracts.
Background Primary Biliary Cholangitis (PBC) is a progressive, autoimmune condition that damages interlobular bile ducts and can lead to end-stage cholestatic liver disease. First line therapy is ursodeoxycholic acid (UDCA) at a dose of 13–15 mg/kg
Publikováno v:
Posters.
Introduction In April 2017, NHS England (NHSE) commissioned the use of obeticholic acid as a licensed treatment option for primary biliary cholangitis (PBC), an autoimmune liver disease which causes progressive destruction in interlobular bile ducts
Autor:
Sital Shah
Publikováno v:
Pharmaceutical Journal.
Autor:
Sital Shah
Publikováno v:
Pharmaceutical Journal.